Tenaya's TN-401 Gene Therapy Achieves 64% Arrhythmia Reduction in Phase 1b/2 Trial; EU PRIME Designation Granted
TNYA has more than doubled off its 52-week low of $0.36.
Summary
Tenaya Therapeutics announced highly positive interim data from its RIDGE™-1 Phase 1b/2 clinical trial of TN-401 gene therapy for PKP2-associated ARVC. The data revealed a mean 64% reduction in daily premature ventricular contractions (PVCs) across all six patients in Cohorts 1 and 2, with TN-401 demonstrating a favorable safety profile. This significant clinical milestone, coupled with the European Medicines Agency's (EMA) PRIME designation for TN-401, provides substantial validation for the company's lead gene therapy program. For a clinical-stage biotech, this positive data de-risks the pipeline considerably and is a major catalyst, indicating strong potential for the therapy to address a life-threatening heart condition. Investors will now closely monitor the full data readouts, progression to pivotal trials, and the accelerated regulatory path afforded by the PRIME designation.
At the time of this announcement, TNYA was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $202.9M. The 52-week trading range was $0.36 to $2.35. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.